Enanta is leveraging its early success with our licensed HCV product, to become a leader in viral and liver diseases. Enanta’s research and development efforts are currently focused on the following disease targets: non-alcoholic steatohepatitis (NASH)/ primary biliary cholangitis (PBC), respiratory syncytial virus (RSV) and hepatitis B virus (HBV). For an overview of our research, including our licensed products, please see Our Pipeline.
NASH & PBC
The World Health Organization (WHO) has declared that NASH and its precursor, Non-alcoholic fatty liver disease, (NAFLD) are now the number one causes of liver disease in Western countries and represent a major global health concern. Primary Biliary Cholangitis (PBC), is another disease of the liver that can result in liver damage, liver failure, or hepatocellular carcinoma.
Enanta’s research in NASH/PBC is initially focused on agonists of the Farnesoid X Receptor (FXR). FXR is a nuclear receptor and a main regulator of bile acid levels in the liver and small intestine. Enanta’s lead candidate, EDP-305, is currently in phase 1. Learn More
RSV is the most common cause of bronchiolitis (inflammation of the small airways in the lung) and pneumonia in children under 1 year of age in the United States. There is currently no effective treatment available for treating RSV infection.
Enanta’s research in RSV is focused on non-fusion inhibitors that target virus replication. Learn More
Hepatitis B is a potentially life-threatening liver infection caused by the hepatitis B virus. It is estimated that 250 million people worldwide are chronically infected, and 15-25% of patients with chronic HBV infection develop chronic liver disease, including cirrhosis, liver cancer, or liver decompensation.
Enanta’s HBV research programs are in preclinical stages and focused on core inhibitors. We continue to make progress in discovering, characterizing and securing patent protecting for new core inhibitors. Learn More